AtriCure Analyst Price Targets - Benzinga

SPY774.46+0.07%QQQ747.75+0.02%BTC/USD82,424.81+0.90%DIA511.79+0.03%GLD379.46+0.22%TLT77.66−0.27%

AtriCure Inc

ATRCNASDAQ

Trade with Public

Trade with Public

$52.84

-0.47-0.88%

Last update: Oct 8, 4:00 PM

$52.84

-0.47-0.88%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

AtriCure Analyst Price Targets - Benzinga

AtriCure Analyst Price Targets

Wall Street analyst price targets and consensus rating for AtriCure (ATRC).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

3S.Buy

7Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$54Upside to Avg. PT+2.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Freedom Capital Markets	Keith Hinton	Downgrade	Buy→Hold	$43→$57
Sep 2, 2026	Needham	Mike Matson	PT Raise	Buy	$45→$64
Aug 27, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$50→$60
Aug 24, 2026	BTIG	Marie Thibault	PT Raise	Buy	$45→$55
Jul 28, 2026	UBS	Priya Sachdeva	PT Cut	Buy	$55→$50
May 6, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$53→$55
Feb 18, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$64→$53
Feb 18, 2026	UBS	Danielle Antalffy	PT Cut	Buy	$60→$55
Feb 18, 2026	Citizens	Daniel Stauder	PT Cut	Market Outperform	$60→$52
Feb 18, 2026	Oppenheimer	Suraj Kalia	Downgrade	Outperform→Perform	—
Feb 18, 2026	BTIG	Marie Thibault	Maintained	Buy	$54
Feb 12, 2026	Needham	Mike Matson	Maintained	Buy	$45
Dec 16, 2025	JP Morgan	Lilia-Celine Lozada	PT Raise	Overweight	$42→$48
Oct 30, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$53→$64
Jul 30, 2025	Needham	Mike Matson	PT Raise	Buy	$44→$45
Apr 30, 2025	BTIG	Marie Thibault	PT Cut	Buy	$58→$52
Apr 30, 2025	UBS	Danielle Antalffy	PT Cut	Buy	$60→$58
Apr 30, 2025	JMP Securities	Daniel Stauder	Maintained	Market Outperform	$60
Apr 30, 2025	Needham	Mike Matson	PT Cut	Buy	$51→$44
Apr 2, 2025	Citizens Capital Markets	Daniel Stauder	Maintained	Market Outperform	$60

More with Benzinga EdgeGet Access

Analyst Ratings News

Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.

Avi Kapoor

This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.

Avi Kapoor

PRO
Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57

Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.

Benzinga Newsdesk

Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised

Avi Kapoor

PRO
Needham Maintains Buy on AtriCure, Raises Price Target to $64

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60

Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.

Benzinga Newsdesk